See Mymee Featured In...
Digitally Tracked Data Improve QOL in Autoimmune Diseases, Long COVID
Prior research suggests that a host of environmental factors known as the human exposome have profound effects on autoimmune onset and activity. However, the complexity of autoimmune diseases has hampered the development of recommendations that are universally beneficial.
The Long and Winding COVID Road
Podcast host Matthew Zachary speaks with Dr. David Putrino, Director Of Rehabilitation Innovation at Icahn School of Medicine at Mount Sinai and returning guest, Mette Dyhrberg, Founder & CEO of Mymee, for a deep dive conversation on the continuing mystery of Long COVID.
Patient-Reported Outcomes Become More Involved in Treating, Managing Rheumatic Diseases in 2022
With a great deal of marginalized patients navigating burdensome, chronic, heterogenetic disease today, evaluating a patient’s self-evidence is helping rheumatologists develop treatment plans that address individual needs and goals.
Patients With Autoimmune Diseases Report Improved QOL With Digital Care
For patients with autoimmune diseases, including those with “long COVID,” a digital care program was found to have high engagement and adherence, and was associated with clinically meaningful improvements in HRQOL, according to findings published in RMD Open.
Self-Advocacy Platform Allows Patients with Autoimmune Diseases to Discover Triggers, Improve Disease Management
CEO and founder Mette Dyhrberg shares how her personal autoimmune journey since age 14 sparked her vision for Mymee in this Q&A about how the company’s personalized trial and care platform is helping others finally gain control of symptoms.
Mette Dyhrberg on the Cure for the Common Co. podcast
Steve Blumenfield, Head of Partnerships & Alliances in WTW’s Innovation group, interviews Mette Dyhrberg about the challenges she faced when she was no longer able to control her autoimmune disease flares with the best of modern medicine and how that led to Mymee's personalized trial and care platform.